Nephrol Dial Transplant (2001) 16: 771-775
© 2001 European Renal Association-European Dialysis and Transplant Association
Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM
1 Departments of Nephrology, 2 Endocrinology and 3 Clinical Pharmacology, University Hospital Groningen, Groningen, The Netherlands
Background. Interference in the renin–angiotensin system with angiotensin-converting enzyme (ACE) inhibitors has proven to be effective in lowering albuminuria in patients with insulin-dependent diabetes mellitus (IDDM). We studied whether angiotensin II receptor antagonism reduces urinary albumin excretion (UAE) in IDDM patients, and the relationship between the antiproteinuric effect and changes in systemic and renal haemodynamics.
Methods. Nine IDDM patients with microalbuminuria (30–300 mg/24 h) were studied. Patients were studied after a 4 week placebo period, on days 3, 7 and 28 of treatment with losartan 50 mg once daily, and after a 4 week placebo-controlled recovery period.
Results. Mean arterial pressure (MAP) was only slightly lowered during losartan treatment. Effective renal plasma flow (ERPF) was significantly increased on the third day of treatment and remained stable throughout the treatment period. Glomerular filtration rate (GFR) did not change throughout the study. Filtration fraction (FF) was maximally lowered on the third day of treatment and remained stable during treatment. UAE was already significantly lowered after 2 days of treatment, during both the day and night, and remained stable throughout the treatment period. The time course of the changes in UAE paralleled that of the changes in MAP, ERPF and FF.
Conclusions. The angiotensin receptor antagonist losartan effectively lowers UAE in microalbuminuric IDDM patients. The changes observed in renal haemodynamics and UAE are concordant in time and maximal within only a few days of treatment. These results support the importance of the specific effects of interference in the renin angiotensin system (RAS) in microalbuminuric IDDM on blood pressure and renal haemodynamics in reducing urinary protein leakage, rather than non-haemodynamic, structural changes of the glomerular basement membrane.
Keywords: insulin-dependent diabetes mellitus; losartan; microalbuminuria; renal haemodynamics
Correspondence and offprint requests to: Prof. P. E. de Jong, Department of Nephrology, University Hospital Groningen, PO Box 30001, 9700 RB Groningen, The Netherlands.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. K. Jacobsen Review: Preventing End-Stage Renal Disease in Diabetic Patients -- Dual Blockade of the Renin-Angiotensin System (Part II) Journal of Renin-Angiotensin-Aldosterone System, June 1, 2005; 6(2): 55 - 68. [Abstract] [PDF]
|
|
|
|
 |
|
 A. A.M. Zandbergen, M. G.A. Baggen, S. W.J. Lamberts, A. H. Bootsma, D. de Zeeuw, and R. J.Th. Ouwendijk Effect of Losartan on Microalbuminuria in Normotensive Patients with Type 2 Diabetes Mellitus: A Randomized Clinical Trial Ann Intern Med, July 15, 2003; 139(2): 90 - 96. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Jacobsen, S. Andersen, B. R. Jensen, and H.-H. Parving Additive Effect of ACE Inhibition and Angiotensin II Receptor Blockade in Type I Diabetic Patients with Diabetic Nephropathy J. Am. Soc. Nephrol., April 1, 2003; 14(4): 992 - 999. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Andersen, P. Jacobsen, L. Tarnow, P. Rossing, T. R. Juhl, and H.-H. Parving Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy Nephrol. Dial. Transplant., February 1, 2003; 18(2): 293 - 297. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Rossing, P. K. Christensen, B. V. Hansen, B. Carstensen, and H.-H. Parving Optimal Dose of Candesartan for Renoprotection in Type 2 Diabetic Patients With Nephropathy: A double-blind randomized cross-over study Diabetes Care, January 1, 2003; 26(1): 150 - 155. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Andersen, P. Rossing, T. R. Juhl, J. Deinum, and H.-H. Parving Optimal dose of losartan for renoprotection in diabetic nephropathy Nephrol. Dial. Transplant., August 1, 2002; 17(8): 1413 - 1418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Jacobsen, S. Andersen, K. Rossing, B. V. Hansen, and H.-H. Parving Dual blockade of the renin-angiotensin system in type 1 patients with diabetic nephropathy Nephrol. Dial. Transplant., June 1, 2002; 17(6): 1019 - 1024. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. A. Houlihan, T. J. Allen, A. L. Baxter, S. Panangiotopoulos, D. J. Casley, M. E. Cooper, and G. Jerums A Low-Sodium Diet Potentiates the Effects of Losartan in Type 2 Diabetes Diabetes Care, April 1, 2002; 25(4): 663 - 671. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A J Devonald and F. E Karet Targeting the renin-angiotensin system in patients with renal disease J R Soc Med, January 8, 2002; 95(8): 391 - 397. [Full Text] [PDF]
|
|